Edinburgh Genome Foundry has invested in a cutting edge system, funded by a £2 million grant from the Biotechnology and Biological Sciences Research Council (BBSRC), that will speed advances in medicine and fast-track other areas of science. Image The Beacon® Optofluidics system from Berkeley Lights The investment in this unique high throughput cell-selection system (Beacon® Optofluidics system from Berkeley Lights) means Edinburgh University is the first institution in Europe, outside of industry, to offer global open-access to this system to academia and industry. It offers lots of scope to speed advances across medicine, biotech and basic research - so it’s a really big opportunity for a wide range of researchers. It will radically improve the speed and ease of developing, analysing and selecting cells that produce the key components of new treatments, therapies and drugs. It will enable advances that mean research projects can rapidly progress to understand and find new ways to tackle disease, and potential treatments can reach clinical trials faster. The system provides researchers with a one-stop shop that automates and simplifies this process - improving accuracy, reducing costs and shortening timescales from months to days. Related links Full press release Edinburgh Genome Foundry UK Centre for Mammalian Synthetic Biology Berkeley Lights, Inc This article was published on 2024-06-17
